# Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

> **NCT03689595** · — · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 30000 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **OTHER:** Sample of Blood

## Key facts

- **NCT ID:** NCT03689595
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2018-10-31
- **Primary completion:** 2033-10-31
- **Final completion:** 2033-10-31
- **Target enrollment:** 30000 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03689595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03689595, "Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03689595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*